
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39223159
71275
10.1038/s41598-024-71275-9
Article
A nomogram with Ki-67 in the prediction of postoperative recurrence and death for glioma
Li Fengfeng 1
Wang Dongyuan 1
Wang Nana 1
Wu Linlin Docbaoqiang3524@outlook.com

2
Yu Bo Docqiang7471@outlook.com

3
1 https://ror.org/03b867n98 grid.508306.8 Neurosurgery Department, Tengzhou Central People’s Hospital Affiliated to Xuzhou Medical University, Tengzhou, China
2 https://ror.org/03b867n98 grid.508306.8 Oncology Department, Tengzhou Central People’s Hospital Affiliated to Xuzhou Medical University, Tengzhou, 277500 China
3 https://ror.org/03b867n98 grid.508306.8 Intensive Care Unit, Tengzhou Central People’s Hospital Affiliated to Xuzhou Medical University, Tengzhou, 277500 China
2 9 2024
2 9 2024
2024
14 2033425 3 2024
26 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
This study examined to evaluate the predictive value of a nomogram with Ki-67 in overall and disease-free survival in glioma patients, a total of 76 patients diagnosed with glioma by pathology in Tengzhou Central People’s Hospital were enrolled. The baseline data and follow ups were retrospectively collected from medical records. The associations between Ki-67 and survival status were examined using log-rank test, univariate and multivariate Cox proportional hazard regression models. Calibrations were performed to validate the established nomograms. Ki-67 negative group showed of a longer OS survival time and a longer PFS survival time with log-rank test (x2 = 16.101, P < 0.001 and x2 = 16.961, P < 0.001). Age older than 50 years (HR = 2.074, 95% CI 1.097–3.923), abnormal treatment (HR = 2.932, 95% CI 1.343–6.403) and Ki-67 positive (HR = 2.722, 95% CI 1.097–6.755) were the independent predictive factors of death. High grade pathology (HR = 2.453, 95% CI 1.010–5.956) and Ki-67 positive (HR = 2.200, 95% CI 1.043–4.639) were the independent predictive factors of recurrence. The C-index for the nomogram of OS and PFS were 0.745 and 0.723, respectively. The calibration results showed that the nomogram could predict the overall and disease-free 1-year survival of glioma patients. In conclusion, the nomograms with Ki-67 as independent risk factor for OS and PFS could provide clinical consultation in the treatment and follow-up of malignant glioma.

Keywords

Nomogram
Glioma
Ki-67
Death
Recurrence
Subject terms

Cancer
Diseases of the nervous system
Experimental models of disease
Xuzhou Medical University Affiliated Hospital Development Fund ProjectXYFY202215 Li Fengfeng issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Glioma is a common malignant tumor originating from the central nervous system, with a growing trend1,2. The age-adjusted average annual incidence rate of glioma was 6.42 per 100,000 population2. Gliomas are classified into low-grade gliomas and high-grade gliomas, which are correlated to the prognosis and used to predict a response to therapy and outcome. The standard therapy includes surgical resection when feasible, radiotherapy, and chemotherapy, but gliomas are prone to recurrence after surgery with short survival time2,3.

Due to the high recurrence and high invasiveness of glioma, it is necessary to explore appropriate diagnostic methods for the prognosis of gliomas4,5. Ki-67 is a nuclear protein located in the nucleus of proliferating cells. It is closely related to the cell cycle and can affect the mitosis of cells6–8. Ki-67 was first applied to the classification and prognosis of breast malignant tumors, and gradually applied to central nervous system tumors9,10.

It is closely related to the synthesis and metabolism of tumor cells in the proliferation cycle, and its appearance can confirm that the cells are in the division phase11,12. Ki-67 proliferation index is more accurate in counting, as a result, its expression can monitor the degree of tumor cell proliferation, the different states of the cell cycle and the rate of tumor cell proliferation. It can be used as a specific index of tumor proliferation, and reflect the malignancy of tumor tissue and judge the prognosis of patients13.

In this study, we constructed the prognostic model of Ki-67 in glioma, which could provide a scientific basis for the diagnosis and treatment of the disease.

Methods and materials

Population and inclusion/exclusion criteria

Patients diagnosed with glioma between 2014 to 2019 in Neurosurgery Department, Tengzhou Central People’s Hospital was enrolled. The baseline data including admission ID, age, gender, marriage, BMI, scales, tumor length and width, epilepsy, pathology, treatment, and followups was retrospectively collected. The length and width of glioma was measured in the maximum cross-sectional area in T2/FLAIR high-intensity lesions of MRI imaging. Patients who received surgery and concurrent postoperative chemoradiation were included. Patients without pathology diagnosis or chemoradiation were excluded. Patients were followed every month for the first year. After the first year, patients were followed every three months. Patients lost to follow-up or survived at the time of last follow-up time were regarded as censored. This study was approved by the Ethics Committee of Tengzhou Central People’s Hospital (Approval No. 2020-31). Baseline data collection from the medical records was conducted in compliance with the declaration of Helsinki. Informed consents were waived.

Ki-67 testing

Ki-67 is a sensitive marker of cell proliferation and positively associated with the malignant degree of glioma14. Up to date, Ki-67 is widely used in pathology to evaluate cell proliferation in malignancies, yet the relationship between Ki-67 and prognosis of glioma remains largely unknown15. The surgically excised glioma tissue was formalin-fixed, paraffin-embedded, and sectioned for pathological diagnosis. The tissue was read by qualified pathologists after the immunohistochemical staining test (detection kit from Maixin Biotechnology Development Co., Ltd) under the 10–40 × high-power microscope. A total of five fields of view were randomly selected to count the staining results of 1000 tumor cells. Positive staining results were defined as yellow staining on the nuclei of glioma cells in tissue sections, positive cells > 10%, 16–18 and no background staining.

Glasgow coma scale

The glasgow coma scale (GCS) is a well-established neurological tool designed to assess the patient’s level of consciousness after brain injury in clinical practice19. The scale evaluates the patient’s best eye response, best verbal response, and best motor response, and then assigns a score that ranges from three to fifteen. This scale is the main method in use for assessment of head injuries20.

Karnofsky performance scale

The karnofsky performance scale (KPS) is one of the most commonly used scale to assess patients’ quality of life and is used to evaluate condition and ability to undergo chemotherapy in glioma patients21. A score between 0 and 100 is assigned by a health professional after watching a patient perform common tasks. Decreasing numbers mean that the patient has less ability to perform activities of daily living. The higher score associated with better health status, which reflecting the higher tolerance to the adverse effects of treatment.

Pathology grade

The pathology grade of the patients was classified by the grading system developed by the world health organization (WHO)22. According to this grading system, gliomas are classified into grades 1 (least malignant, best prognosis) to grade 4 (most malignant, worst prognosis). Gliomas can be further classified according to the pathological malignancy of tumor cells: low-grade gliomas (WHO grades 1–2) and high-grade gliomas (WHO grades 3–4).

Patient and public involvement

In a retrospective analysis of an anonymous hospital inpatient database, no public or patient participation was involved.

Statistical analysis

Continuous variables were described using median (range) and compared with Mann–Whitney test. Categorical variables were described using frequency (percentage) and compared using chi-square test. The survival curves were plotted using the Kaplan–Meier method, and log-rank test was used for statistical analysis. The associations between Ki-67 and survival status were examined using univariate and multivariate Cox proportional hazard regression models. Univariate Cox proportional hazard analysis was performed to identify risk factors of death and recurrence and Hazard Ratio (HR) with 95% Confidence Interval (95% CI) of potential risk factors was displayed. Multivariate Cox proportional hazard regression analysis was used to select independent influence factors and nomograms were built based mainly on these results. Harrell’s concordance index (C-index) was used to assess the reliability of the nomogram. Calibration for the established nomograms were performed and 1000 repetitions of bootstrap sample corrections were applied to internally validate the nomograms. All statistical tests were two-sided using a 0.05 significance level. The data analyses and nomograms were performed using R software version 3.4.3.

Results

Descriptive analysis of the patient population

Overall, 76 patients were included in the final data analysis (Table 1). In total, there were 44.74% of the patients under the age of 50 years old, while 55.26% of the patients were older than 50 years old. Males accounted for 57.89% of the total patients. The median BMI was 23.70 (12.40–29.37) kg/m2. The median GCS and KPS scores were 15.00 (3.00–15.00) and 90.00 (10.00–100.00), respectively. The median tumor length and width were 5.20 (1.20–8.00) cm and 3.90 (1.00–5.70) cm, respectively. The pathology grades were 26.32% of low grade and 73.68% of high grade. Only 32.89% of glioma patients received normal treatment.Table 1 Demographic characteristics of the enrolled patients.

Characteristics	Total (n = 76)	Ki67 negative (Ki67 <  = 10%) (n = 32)	Ki67 positive (Ki67 > 10%)(n = 44)	P	
Age (years)	 ≤ 50	34 (44.74)	16 (50.0)	18 (40.91)	0.431	
 > 50	42 (55.26)	16 (50.0)	26 (59.09)		
Gender	Female	32 (42.11)	18 (56.25)	14 (31.82)	0.033	
Male	44 (57.89)	14 (43.75)	30 (68.18)		
Marriage*	No	7 (9.21)	2 (6.25)	5 (11.36)	0.692	
Yes	69 (90.79)	30 (93.75)	39 (88.64)		
BMI	23.70 (12.40–29.37)	23.78 (17.93–29.37)	23.43 (12.40–26.17)	0.542	
GCS score	15.00 (3.00–15.00)	15.00 (3.00–15.00)	15.00 (11.00–15.00)	0.886	
KPS score	90.00 (10.00–100.00)	90.00 (10.00–100.00)	90.00 (10.00–90.00)	0.745	
Tumor length (cm)	5.20 (1.20–8.00)	4.75 (1.70–8.00)	5.65 (1.20–8.00)	0.103	
Tumor width (cm)	3.90 (1.00–5.70)	3.60 (1.10–5.70)	4.20 (1.00–5.00)	0.199	
Epilepsy*	No	66 (86.84)	24 (75.00)	42 (95.45)	0.014	
Yes	10 (13.16)	8 (25.00)	2 (4.55)		
Pathology	Low grade	20 (26.32)	19 (59.38)	1 (2.27)	 < 0.001	
High grade	56 (73.68)	13 (40.63)	43 (97.73)		
Normal treatment	Yes	25 (32.89)	12 (37.50)	13 (29.55)	0.466	
No	51 (67.11)	20 (62.50)	31 (70.45)		

A total of 32 patients were Ki-67 negative (Ki-67 ≤ 10%) and 44 patients were Ki-67 positive (Ki-67 > 10%). The females in Ki-67 negative group accounted higher percentage than in Ki-67 positive group (P = 0.033). The pathology grades in Ki-67 negative group were lower than in Ki-67 positive group (P < 0.001). Other demographic and clinical characteristics showed no significance in the two groups.

Ki-67 and other risk factors of death and recurrence in glioma

The median overall survival (OS) time was 28.9 months in Ki-67 negative group, and 8.1 months in Ki-67 positive group (Fig. 1A). The median progression-free survival (PFS) time was 18.1 months in Ki-67 negative group, and 5.2 months in Ki-67 positive group (Fig. 1B). In the OS and PFS curves, Ki-67 negative group showed of a longer OS survival time and a longer PFS survival time with log-rank test (x2 = 16.101, P < 0.001 and x2 = 16.961, P < 0.001).Fig. 1 The overall all survival (A) and progression-free survival (B) curves between Ki-67 negative and Ki-67 positive.

In the univariate Cox regression model of death (Table 2), age older than 50 years, high grade pathology, abnormal treatment and Ki-67 positive were the risk factors of death in glioma patients (all P < 0.05). In the multivariate analysis, age older than 50 years (HR = 2.074, 95% CI 1.097–3.923), abnormal treatment (HR = 2.932, 95% CI 1.343–6.403) and Ki-67 positive (HR = 2.722, 95% CI 1.097–6.755) were the independent predictive factors of death in glioma patients (P = 0.025, 0.007 and 0.032, respectively).Table 2 The Cox proportion hazard regression on the death risk of brain glioma.

Characteristics	Univariate Cox regression	Multivariate Cox regression	
HR	95% CI	P	HR	95% CI	P	
Age	 ≤ 50 years	1			1			
 > 50 years	1.900	1.025–3.524	0.042	2.074	1.097–3.923	0.025	
Gender	Female	1						
Male	1.065	0.583–1.946	0.837				
Marriage	No	1						
Yes	1.166	0.414–3.284	0.771				
BMI	 < 24	1						
 ≥ 24	1.169	0.645–2.119	0.606				
GCS score	15	1						
 < 15	0.834	0.328–2.120	0.703				
KPS score	 ≥ 90	1						
 < 90	1.096	0.525–2.289	0.807				
Tumor length	 < 5 cm	1						
 ≥ 5 cm	1.243	0.687–2.250	0.472				
Tumor width	 < 4 cm	1						
 ≥ 4 cm	1.24	0.681–2.259	0.482				
Epilepsy	No	1						
Yes	0.444	0.158–1.250	0.124				
Pathology	Low grade	1			1			
High grade	4.126	1.792–9.497	 < 0.001	1.999	0.668–5.984	0.216	
Normal treatment	Yes	1			1			
No	2.788	1.290–6.027	0.009	2.932	1.343–6.403	0.007	
Ki-67	Negative (≤ 10%)	1			1			
Positive (> 10%)	3.791	1.898–7.572	 < 0.001	2.722	1.097–6.755	0.031	

In the univariate Cox regression model of recurrence (Table 3), high grade pathology and Ki-67 positive were the risk factors of recurrence in glioma patients (both P < 0.001). In the multivariate analysis, high grade pathology (HR = 2.453, 95% CI 1.010–5.956) and Ki-67 positive (HR = 2.200, 95% CI 1.043–4.639) were the independent predictive factors of recurrence in glioma patients (P = 0.047 and 0.038, respectively).Table 3 The Cox proportion hazard regression on the recurrence risk of brain glioma.

Characteristics	Univariate Cox regression	Multivariate Cox regression	
HR	95% CI	P	HR	95% CI	P	
Age	 ≤ 50 years	1			1			
 > 50 years	1.332	0.774–2.291	0.300	1.335	0.772–2.309	0.301	
Gender	Female	1						
Male	1.308	0.755–2.265	0.338				
Marriage	No	1						
Yes	1.989	0.702–5.635	0.196				
BMI	 < 24	1						
 ≥ 24	1.319	0.772–2.254	0.311				
GCS score	15	1						
 < 15	0.615	0.261–1.449	0.266				
KPS score	 ≥ 90	1						
 < 90	0.964	0.494–1.879	0.914				
Tumor length	 < 5 cm	1						
 ≥ 5 cm	1.375	0.803–2.352	0.246				
Tumor width	 < 4 cm	1						
 ≥ 4 cm	1.342	0.779–2.310	0.289				
Epilepsy	No	1						
Yes	0.523	0.222–1.235	0.139				
Pathology	Low grade	1			1			
High grade	3.818	1.833–7.953	 < 0.001	2.453	1.010–5.956	0.047	
Normal treatment	Yes	1			1			
No	1.233	0.691–2.202	0.478	1.133	0.628–2.045	0.678	
Ki-67	Negative (≤ 10%)	1			1			
Positive (> 10%)	3.604	1.894–6.857	 < 0.001	2.200	1.043–4.639	0.038	

A nomogram for the prediction of death and recurrence in glioma patients

In combination of the risk factors of death and recurrence, the risk factors of age, Ki-67, pathology grade and treatment were used to develop predictive nomograms for the glioma patients.

For each patient, points were assigned for each of these demographic and clinical factors (age, Ki-67, pathology, and treatment), then a total score and a corresponding 1-year, 2-year and 3-year predicted the probability of OS and PFS were calculated from the nomograms (Fig. 2 (Figs. 2, 3) Fig. 3). The C-index for the nomogram of OS was 0.745, while the C-index for the nomogram of PFS was 0.723. All calibration plots for the probability of OS and PFS fit well. The calibration results showed that the nomogram could predict the overall and disease-free 1-year survival of glioma patients.Fig. 2 The nomogram (A) and calibration (B) in the prediction of death in glioma patients.

Fig. 3 The nomogram (A) and calibration (B) in the prediction of recurrence in glioma patients.

Discussion

As a risk prediction and assessment tool, nomogram has broadly used in clinical interpretation, and have been widely adopted in prognostic models23–25. However, it is rarely used in the prognosis of glioma patients26,27. In this study, we established a nomogram-based method to predict the OS and PFS. The nomogram exhibited the ability to predict the OS and PFS according to the calibration curves.

In this study, the nomogram consisted of four prognostic factors according to the multivariate Cox regression model. Age, Ki-67 expression level, pathology grade and treatment were included in both the nomogram of OS and PFS. Older age, higher Ki-67 expression, higher pathology grade and abnormal treatment were associated with poor survival in glioma patients.

Generally, one of the common risk factors for cancer was ageing28–30. Age was associated with OS in the Cox regression nomogram in this study. Almost half of the patients enrolled in this study were under 50 years old. A study from the cancer genome atlas (TCGA) dataset also showed that age at initial pathologic diagnosis was most associated with the overall survival of LGG patients (P < 0.001 and HR = 19.8), which might be caused by the profiles of genomic alterations31. In addition, other host-derived factors, such as age-related immune alterations, might play an important role in the poor prognosis observed in these patients32.

Previous studies showed that histological subtype was one of the most important prognostic factors of WHO grade 3 gliomas. Surgery, chemotherapy, and radiotherapy have been the most effective glioma treatment methods up to date33. The consistent application of the multimodal treatment options for glioma has led in recent years to improved survival34. In our study, patients received normal treatment showed a longer survival time. The results prompted that the survival rate could be improved and the treatment methods played an important role in the survival of malignant gliomas.

Ki-67 was widely used as a biomarker of cell proliferation, which was associated with the pathology grade and malignant degree for glioma35–37. The cut-off value of Ki-67 high expression was defined as 10%, which was consistent with previous studies38–40. Our results showed that Ki-67 expressed significant higher in high grade glioma (Grade 3–4), which meant Ki-67 could be related to the pathology and prognosis in glioma patients. A previous study by Liu et al. showed that Ki-67 was highest in WHO grade IV tumors with statistically significance41. Another study by Yuan et al. also showed that the high expression rate of Ki-67 in patients with grade I-II brain glioma was significantly lower compared with patients with grade III-IV glioma42. These consistent results showed that Ki-67 might be a potential biomarker in the prognostic of glioma.

One the other hand, the studies on Ki-67 as a prognostic marker has been limited, especially in the prognosis of recurrence in glioma patients. A retrospective study showed that high Ki-67 expression were significantly associated with OS in multivariate Cox analyses with HR = 3.40 (1.64–7.02) in low-grade glioma, but not significantly associated with PFS (HR = 1.607 (0.93–2.77), P = 0.09). In anaplastic gliomas and glioblastomas, high Ki-67 expression were significantly associated with PFS in multivariate Cox analyses with HR = 1.25 (1.01–1.54), but not significantly associated with OS (HR = 1.09 (0.85–1.39), P = 0.49)43. In our study, the results showed that the high expression of Ki-67 were both significant in OS and PFS in glioma patients, with the HR of 2.722 (95% CI 1.097–6.755) and 2.200 (95% CI 1.043–4.639). The results showed that Ki-67 potentially associated with the prognosis of glioma.

There are also some limitations in our nomogram-based model. The limited sample size and single center dataset would bring bias in the credibility of the risk prediction model. Up to date, our nomogram considered Ki-67 as a molecular marker in the prediction of survival and recurrence in glioma, which would help improve the nomogram built by Zhao et al. previously26. A more detailed pathology classification should be considered in the future in a large sample size multicenter study when the nomogram would be further improved.

And depending on the institution's capabilities or facilities, IDH mutation could not be checked. It is now an era in which glioma research especially in high-grade gliomas cannot be talked about except for molecular diagnosis. The lack of analytical diagnostic data makes our nomogram less reliable. As our technological capabilities continue to improve in the future, the subsequent studies on glioma will be distinguished from the presence or absence of IDH mutation.

Conclusion

The study provided a predictive tool with Ki-67 in glioma patients. The nomograms for OS and PFS could provide clinical consultation in the treatment and follow-up of malignant glioma.

Acknowledgements

Thanks for the fully support and help of Professor Jijun Xu from the department of neurosurgery, Tengzhou Central People’s Hospital Affiliated to Xuzhou Medical University and Dr. Mingrui Song from the department of pathology, Tengzhou Central People's Hospital Affiliated to Xuzhou Medical University.

Author contributions

Original Draft Preparation, FFL; Review and Editing, LLW, BY; Data collection, FFL, DYW, NNW, LLW and BY. All authors reviewed the manuscript.

Funding

This study is funded by Xuzhou Medical University Affiliated Hospital Development Fund Project (Grant Number: XYFY202215).

Data availability

The authors declare that all experimental data supporting this study are available from the corresponding author upon reasonable request.

Competing interests

The authors declare no competing interests.

Ethical approval

This study was approved by the Ethics Committee of Tengzhou Central People’s Hospital Affiliated to Xuzhou Medical University (Approval No. 2020-31).

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Fisher JL Schwartzbaum JA Wrensch M Epidemiology of brain tumors Neurol. Clin. 2007 25 4 867 890 10.1016/j.ncl.2007.07.002 17964019
Fisher, J. L. et al. Epidemiology of brain tumors. Neurol. Clin. 25(4), 867–890. 10.1016/j.ncl.2007.07.002 (2007).17964019 10.1016/j.ncl.2007.07.002
2. Wen PY Kesari S Malignant gliomas in adults N. Engl. J. Med. 2008 359 5 492 507 10.1056/NEJMra0708126 18669428
Wen, P. Y. & Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 359(5), 492–507. 10.1056/NEJMra0708126 (2008).18669428 10.1056/NEJMra0708126
3. Westermark B Glioblastoma—A moving target Ups. J. Med. Sci. 2012 117 2 251 256 10.3109/03009734.2012.676574 22512247
Westermark, B. Glioblastoma—A moving target. Ups. J. Med. Sci. 117(2), 251–256. 10.3109/03009734.2012.676574 (2012).22512247 10.3109/03009734.2012.676574
4. Butowski NA Sneed PK Chang SM Diagnosis and treatment of recurrent high-grade astrocytoma J. Clin. Oncol. 2006 24 8 1273 1280 10.1200/JCO.2005.04.7522 16525182
Butowski, N. A., Sneed, P. K. & Chang, S. M. Diagnosis and treatment of recurrent high-grade astrocytoma. J. Clin. Oncol. 24(8), 1273–1280. 10.1200/JCO.2005.04.7522 (2006).16525182 10.1200/JCO.2005.04.7522
5. Wen PY Yung WK Lamborn KR Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American brain tumor consortium study 99–08 Clin. Cancer Res. 2006 12 16 4899 4907 10.1158/1078-0432.CCR-06-0773 16914578
Wen, P. Y. et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American brain tumor consortium study 99–08. Clin. Cancer Res. 12(16), 4899–4907. 10.1158/1078-0432.CCR-06-0773 (2006).16914578 10.1158/1078-0432.CCR-06-0773
6. Haroon S Hashmi AA Khurshid A Ki67 index in breast cancer: Correlation with other prognostic markers and potential in pakistani patients Asian Pac. J. Cancer Prev. 2013 14 7 4353 4358 10.7314/apjcp.2013.14.7.4353 23992002
Haroon, S. et al. Ki67 index in breast cancer: Correlation with other prognostic markers and potential in pakistani patients. Asian Pac. J. Cancer Prev. 14(7), 4353–4358. 10.7314/apjcp.2013.14.7.4353 (2013).23992002 10.7314/apjcp.2013.14.7.4353
7. Healey MA Hirko KA Beck AH Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the nurses’ health study Breast Cancer Res. Treat. 2017 166 2 613 622 10.1007/s10549-017-4421-3 28791482
Healey, M. A. et al. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the nurses’ health study. Breast Cancer Res. Treat. 166(2), 613–622. 10.1007/s10549-017-4421-3 (2017).28791482 10.1007/s10549-017-4421-3
8. Genc CG Falconi M Partelli S Recurrence of pancreatic neuroendocrine tumors and survival predicted by Ki67 Ann. Surg. Oncol. 2018 25 8 2467 2474 10.1245/s10434-018-6518-2 29789972
Genc, C. G. et al. Recurrence of pancreatic neuroendocrine tumors and survival predicted by Ki67. Ann. Surg. Oncol. 25(8), 2467–2474. 10.1245/s10434-018-6518-2 (2018).29789972 10.1245/s10434-018-6518-2
9. Heegaard SS Helle B Proliferating cell nuclear antigen and Ki-67 lmmunohistochemistry of oligodendrogliomas with special reference to prognosis Cancer 1995 76 10 1809 1813 10.1002/1097-0142(19951115)76:10<1809::AID-CNCR2820761020>3.0.CO;2-I 8625052
Heegaard, S. S. & Helle, B. Proliferating cell nuclear antigen and Ki-67 lmmunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 76(10), 1809–1813 (1995).8625052 10.1002/1097-0142(19951115)76:10<1809::AID-CNCR2820761020>3.0.CO;2-I
10. Bredel M Piribauer M Marosi C High expression of DNA topoisomerase IIa and Ki-67 antigen is associated with prolonged survival in glioblastoma patients Eur. J. Cancer 2002 38 10 1343 1347 10.1016/s0959-8049(02)00065-5 12091064
Bredel, M. et al. High expression of DNA topoisomerase IIa and Ki-67 antigen is associated with prolonged survival in glioblastoma patients. Eur. J. Cancer 38(10), 1343–1347. 10.1016/s0959-8049(02)00065-5 (2002).12091064 10.1016/s0959-8049(02)00065-5
11. Liu Y Tang K Yan W Identifying Ki-67 specific miRNA-mRNA interactions in malignant astrocytomas Neurosci. Lett. 2013 546 36 41 10.1016/j.neulet.2013.04.030 23643983
Liu, Y. et al. Identifying Ki-67 specific miRNA-mRNA interactions in malignant astrocytomas. Neurosci. Lett. 546, 36–41. 10.1016/j.neulet.2013.04.030 (2013).23643983 10.1016/j.neulet.2013.04.030
12. Okita Y Narita Y Miyakita Y Pathological findings and prognostic factors in recurrent glioblastomas Brain Tumor Pathol. 2012 29 4 192 200 10.1007/s10014-012-0084-2 22331317
Okita, Y. et al. Pathological findings and prognostic factors in recurrent glioblastomas. Brain Tumor Pathol. 29(4), 192–200. 10.1007/s10014-012-0084-2 (2012).22331317 10.1007/s10014-012-0084-2
13. Hu X Miao WEI Zou Y Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine-DNA methyltransferase in human gliomas Oncol. Lett. 2013 6 1 130 134 10.3892/ol.2013.1317 23946790
Hu, X. et al. Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine-DNA methyltransferase in human gliomas. Oncol. Lett. 6(1), 130–134. 10.3892/ol.2013.1317 (2013).23946790 10.3892/ol.2013.1317
14. Xu G Li C Wang Y Correlation between preoperative inflammatory markers, Ki-67 and the pathological grade of glioma Medicine (Baltimore) 2021 100 36 e26750 10.1097/MD.0000000000026750 34516487
Xu, G. et al. Correlation between preoperative inflammatory markers, Ki-67 and the pathological grade of glioma. Medicine (Baltimore) 100(36), e26750. 10.1097/MD.0000000000026750 (2021).34516487 10.1097/MD.0000000000026750
15. Wang T Niu X Gao T Molecular characteristics of thalamic gliomas in adults J. Mol. Neurosci. 2021 71 8 1598 1604 10.1007/s12031-021-01796-9 33523385
Wang, T. et al. Molecular characteristics of thalamic gliomas in adults. J. Mol. Neurosci. 71(8), 1598–1604. 10.1007/s12031-021-01796-9 (2021).33523385 10.1007/s12031-021-01796-9
16. Chen WJ He DS Tang RX Ki-67 is a valuable prognostic factor in gliomas: Evidence from a systematic review and meta-analysis ASIAN Pac. J. Cancer Prev. 2015 16 2 411 420 10.7314/apjcp.2015.16.2.411 25684464
Chen, W. J. et al. Ki-67 is a valuable prognostic factor in gliomas: Evidence from a systematic review and meta-analysis. ASIAN Pac. J. Cancer Prev. 16(2), 411–420. 10.7314/apjcp.2015.16.2.411 (2015).25684464 10.7314/apjcp.2015.16.2.411
17. Daniele A Alessandro F Maurizio S Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter progression free survival? A clinical and Molecular analytic investigation Clin. Neurol. Neurosurg. 2020 198 106126 10.1016/j.clineuro.2020.106126 32861131
Daniele, A. et al. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter progression free survival? A clinical and Molecular analytic investigation. Clin. Neurol. Neurosurg. 198, 106126. 10.1016/j.clineuro.2020.106126 (2020).32861131 10.1016/j.clineuro.2020.106126
18. Wen JC De SH Rui XT Ki-67 is a valuable prognostic factor in gliomas: Evidence from a systematic review and meta-analysis Asian Pac. J. Cancer Prev. 2015 16 2 411 420 10.7314/apjcp.2015.16.2.411 25684464
Wen, J. C. et al. Ki-67 is a valuable prognostic factor in gliomas: Evidence from a systematic review and meta-analysis. Asian Pac. J. Cancer Prev. 16(2), 411–420. 10.7314/apjcp.2015.16.2.411 (2015).25684464 10.7314/apjcp.2015.16.2.411
19. Cook NF The glasgow coma scale: A European and global perspective on enhancing practice Crit. Care Nurs. Clin. N. Am. 2021 33 1 89 99 10.1016/j.cnc.2020.10.005
Cook, N. F. The glasgow coma scale: A European and global perspective on enhancing practice. Crit. Care Nurs. Clin. N. Am. 33(1), 89–99. 10.1016/j.cnc.2020.10.005 (2021).10.1016/j.cnc.2020.10.005
20. Teasdale G Maas A Lecky F The glasgow coma scale at 40 years: Standing the test of time Lancet Neurol. 2014 13 8 844 854 10.1016/s1474-4422(14)70120-6 25030516
Teasdale, G. et al. The glasgow coma scale at 40 years: Standing the test of time. Lancet Neurol. 13(8), 844–854. 10.1016/s1474-4422(14)70120-6 (2014).25030516 10.1016/s1474-4422(14)70120-6
21. Gunawan PY Islam AA July J Karnofsky performance scale and neurological assessment of neuro-oncology scale as early predictor in glioma Asian Pac. J. Cancer Prev. 2020 21 11 3387 3392 10.31557/APJCP.2020.21.11.3387 33247700
Gunawan, P. Y. et al. Karnofsky performance scale and neurological assessment of neuro-oncology scale as early predictor in glioma. Asian Pac. J. Cancer Prev. 21(11), 3387–3392. 10.31557/APJCP.2020.21.11.3387 (2020).33247700 10.31557/APJCP.2020.21.11.3387
22. Wesseling P Capper D WHO 2016 classification of gliomas Neuropathol. Appl. Neurobiol. 2018 44 2 139 150 10.1111/nan.12432 28815663
Wesseling, P. & Capper, D. WHO 2016 classification of gliomas. Neuropathol. Appl. Neurobiol. 44(2), 139–150. 10.1111/nan.12432 (2018).28815663 10.1111/nan.12432
23. Fakhry C Zhang Q Nguyen-Tân PF Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer J. Clin. Oncol. 2017 35 36 4057 4065 10.1200/JCO.2016.72.0748 28777690
Fakhry, C. et al. Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer. J. Clin. Oncol. 35(36), 4057–4065 (2017).28777690 10.1200/JCO.2016.72.0748
24. Go SI Park S Kim JH A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma Tumori J. 2018 104 4 292 299 10.5301/tj.5000694
Go, S. I. et al. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma. Tumori J. 104(4), 292–299. 10.5301/tj.5000694 (2018).10.5301/tj.5000694
25. Paik ES Sohn I Baek SY Nomograms predicting platinum sensitivity, progression-free survival, and overall survival using pretreatment complete blood cell counts in epithelial ovarian cancer Cancer Res. Treat. 2017 49 3 635 642 10.4143/crt.2016.282 27669704
Paik, E. S. et al. Nomograms predicting platinum sensitivity, progression-free survival, and overall survival using pretreatment complete blood cell counts in epithelial ovarian cancer. Cancer Res. Treat. 49(3), 635–642. 10.4143/crt.2016.282 (2017).27669704 10.4143/crt.2016.282
26. Zhao YY Chen SH Hao Z A nomogram for predicting individual prognosis of patients with low-grade glioma World Neurosurg. 2019 130 e605 e612 10.1016/j.wneu.2019.06.169 31319188
Zhao, Y. Y. et al. A nomogram for predicting individual prognosis of patients with low-grade glioma. World Neurosurg. 130, e605–e612. 10.1016/j.wneu.2019.06.169 (2019).31319188 10.1016/j.wneu.2019.06.169
27. Gittleman H Lim D Kattan MW An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology RTOG 0525 and 0825 Neuro. Oncol. 2017 19 5 669 677 10.1093/neuonc/now208 28453749
Gittleman, H. et al. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology RTOG 0525 and 0825. Neuro. Oncol. 19(5), 669–677. 10.1093/neuonc/now208 (2017).28453749 10.1093/neuonc/now208
28. Arvold ND Reardon DA Treatment options and outcomes for glioblastoma in the elderly patient Clin. Interv. Aging 2014 9 357 367 10.2147/CIA.S44259 24591820
Arvold, N. D. & Reardon, D. A. Treatment options and outcomes for glioblastoma in the elderly patient. Clin. Interv. Aging 9, 357–367. 10.2147/CIA.S44259 (2014).24591820 10.2147/CIA.S44259
29. Stoll EA Horner PJ Rostomily RC The impact of age on oncogenic potential: Tumor-initiating cells and the brain microenvironment Aging Cell 2013 12 5 733 741 10.1111/acel.12104 23711239
Stoll, E. A., Horner, P. J. & Rostomily, R. C. The impact of age on oncogenic potential: Tumor-initiating cells and the brain microenvironment. Aging Cell 12(5), 733–741. 10.1111/acel.12104 (2013).23711239 10.1111/acel.12104
30. Wiestler B Claus R Hartlieb SA Malignant astrocytomas of elderly patients lack favorable molecular markers: An analysis of the NOA-08 study collective Neuro. Oncol. 2013 15 8 1017 1026 10.1093/neuonc/not043 23595628
Wiestler, B. et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: An analysis of the NOA-08 study collective. Neuro. Oncol. 15(8), 1017–1026. 10.1093/neuonc/not043 (2013).23595628 10.1093/neuonc/not043
31. Wang H Wang X Xu L Prognostic significance of age related genes in patients with lower grade glioma J. Cancer 2020 11 13 3986 3999 10.7150/jca.41123 32328202
Wang, H. et al. Prognostic significance of age related genes in patients with lower grade glioma. J. Cancer 11(13), 3986–3999. 10.7150/jca.41123 (2020).32328202 10.7150/jca.41123
32. Gallego Perez-Larraya J Delattre JY Management of elderly patients with gliomas Oncologist 2014 19 12 1258 1267 10.1634/theoncologist.2014-0170 25342314
Gallego Perez-Larraya, J. & Delattre, J. Y. Management of elderly patients with gliomas. Oncologist 19(12), 1258–1267. 10.1634/theoncologist.2014-0170 (2014).25342314 10.1634/theoncologist.2014-0170
33. Weller M van den Bent M Tonn JC European association for neuro-oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas Lancet Oncol. 2017 18 6 e315 e329 10.1016/s1470-2045(17)30194-8 28483413
Weller, M. et al. European association for neuro-oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 18(6), e315–e329. 10.1016/s1470-2045(17)30194-8 (2017).28483413 10.1016/s1470-2045(17)30194-8
34. Goldbrunner R Ruge M Kocher M The treatment of gliomas in adulthood Dtsch. Arztebl. Int. 2018 115 20–21 356 364 10.3238/arztebl.2018.0356 29914619
Goldbrunner, R. et al. The treatment of gliomas in adulthood. Dtsch. Arztebl. Int. 115(20–21), 356–364. 10.3238/arztebl.2018.0356 (2018).29914619 10.3238/arztebl.2018.0356
35. Sun J Li DM Huang J The correlation between the expression of ADAM17, EGFR and Ki-67 in malignant glioma Eur. Rev. Med. Pharmacol. Sci. 2017 21 20 4595 4599 29131255
Sun, J. et al. The correlation between the expression of ADAM17, EGFR and Ki-67 in malignant glioma. Eur. Rev. Med. Pharmacol. Sci. 21(20), 4595–4599 (2017).29131255
36. Wang X Liu X Chen Y Histopathological findings in the peritumoral edema area of human glioma Histol. Histopathol. 2015 30 9 1101 1109 10.14670/HH-11-607 25780990
Wang, X. et al. Histopathological findings in the peritumoral edema area of human glioma. Histol. Histopathol. 30(9), 1101–1109. 10.14670/HH-11-607 (2015).25780990 10.14670/HH-11-607
37. Maldonado F Fabregas N Aldecoa I Association between preoperative serum lactate concentrate with tumor cell proliferative index in primary brain tumor J. Neurosurg. Sci. 2022 66 2 91 95 10.23736/S0390-5616.19.04715-5 31565905
Maldonado, F. et al. Association between preoperative serum lactate concentrate with tumor cell proliferative index in primary brain tumor. J. Neurosurg. Sci. 66(2), 91–95. 10.23736/S0390-5616.19.04715-5 (2022).31565905 10.23736/S0390-5616.19.04715-5
38. Habberstad AH Gulati S Torp SH Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIalpha in human anaplastic astrocytomas—An immunohistochemical study Diagn. Pathol. 2011 6 43 10.1186/1746-1596-6-43 21609421
Habberstad, A. H., Gulati, S. & Torp, S. H. Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIalpha in human anaplastic astrocytomas—An immunohistochemical study. Diagn. Pathol. 6, 43. 10.1186/1746-1596-6-43 (2011).21609421 10.1186/1746-1596-6-43
39. Uematsu M Ohsawa I Aokage T Prognostic significance of the immunohistochemical index of survivin in glioma: A comparative study with the MIB-1 index J. Neurooncol. 2005 72 3 231 238 10.1007/s11060-004-2353-3 15937645
Uematsu, M. et al. Prognostic significance of the immunohistochemical index of survivin in glioma: A comparative study with the MIB-1 index. J. Neurooncol. 72(3), 231–238. 10.1007/s11060-004-2353-3 (2005).15937645 10.1007/s11060-004-2353-3
40. Abd El Atti RM Abou Gabal HH Osman WM Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors Diagn. Pathol. 2013 8 126 10.1186/1746-1596-8-126 23902708
Abd El Atti, R. M. et al. Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors. Diagn. Pathol. 8, 126. 10.1186/1746-1596-8-126 (2013).23902708 10.1186/1746-1596-8-126
41. Liu J SPHK2 protein expression, Ki-67 index and infiltration of tumor-associated macrophages (TAMs) in human glioma Histol. Histopathol. 2018 33 9 987 994 10.14670/HH-11-995 29697136
Liu, J. et al. SPHK2 protein expression, Ki-67 index and infiltration of tumor-associated macrophages (TAMs) in human glioma. Histol. Histopathol. 33(9), 987–994. 10.14670/HH-11-995 (2018).29697136 10.14670/HH-11-995
42. Yuan X Liu D Wang Y Significance of nuclear magnetic resonance combined with Ki-67 and VEGF detection in the diagnosis and prognosis evaluation of brain glioma J. BUON 2018 23 2 410 415 29745085
Yuan, X. et al. Significance of nuclear magnetic resonance combined with Ki-67 and VEGF detection in the diagnosis and prognosis evaluation of brain glioma. J. BUON 23(2), 410–415 (2018).29745085
43. Yang P Wang Y Peng X Management and survival rates in patients with glioma in China (2004–2010): A retrospective study from a single-institution J. Neurooncol. 2013 113 2 259 266 10.1007/s11060-013-1103-9 23483435
Yang, P. et al. Management and survival rates in patients with glioma in China (2004–2010): A retrospective study from a single-institution. J. Neurooncol. 113(2), 259–266. 10.1007/s11060-013-1103-9 (2013).23483435 10.1007/s11060-013-1103-9
